Immunotherapy

Nivolumab-Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer

Wayne Kuznar

December 2018, Vol 8, No 12 - Immunotherapy

The combination of immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) may soon represent a new first-line treatment option in patients with early-stage metastatic colorectal cancer (CRC) associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Two studies presented at the ESMO 2018 Congress demonstrated the efficacy of this combination in this patient population. [ Read More ]

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

November 2018, Vol 8, No 11 - Immunotherapy

The second-generation chimer­ic antigen receptor (CAR) T-cell therapy bb2121, engineered to target B-cell maturation antigen (BCMA), a protein on the surface of certain myeloma cells, displayed continuing efficacy and safety in an update of a phase 1 clinical trial in patients with relapsed or refractory multiple myeloma, according to data presented at ASCO 2018. Currently, no CAR T-cell therapy has been approved for patients with multiple myeloma. [ Read More ]

Immunotherapy Combinations “Raising the Bar”

Phoebe Starr

November 2018, Vol 8, No 11 - Immunotherapy

Immunotherapy combinations are being studied intensively to determine which combinations hold the most promise in specific cancer types. At ASCO 2018, the session “Compelling Combinations: Raising the Bar with Immunotherapy,” which featured 3 new studies that explore chemotherapy plus immunotherapy, got high marks from lead investigator Sibylle Loibl, MD, PhD, Co-chair of the German Breast Group, Neu-Isenburg, Germany, who discussed the results. [ Read More ]

Tabelecleucel Shows High Response Rates in Patients with EBV-Associated Posttransplant Lymphoma Refractory to Rituximab

Walter Alexander

October 2018, Vol 8, No 10 - Immunotherapy

Patients with Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorders (PTLD) who do not respond to first-line rituximab (Rituxan) therapy are extremely difficult to manage, said Susan E. Prockop, MD, Pediatric Oncologist, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2018 European Hematology Association Congress. [ Read More ]